Sweeney et al. suggested a different etiopathogenesis of ameloblastoma, proposing a molecular-based classification of these lesions, potentially responsive to different targeted therapy: SMO-mutated lesions, typical of early relapsing, maxillary plexiform ameloblastomas, and mandibular BRAF-mutated tumors.19,24,26 Our results support this hypothesis which could indicate the anatomic specificity of the driving mutations, suggesting a different developmental signaling pathway.16,19,24,26,36,40,42,43. Here, BRAF is linked to ameloblastoma.